☆ 4.7 Letter

Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

DIABETES OBESITY & METABOLISM (2023)

Get Full Text
Add to Collection

Journal

DIABETES OBESITY & METABOLISM
Volume 25, Issue 7, Pages 2038-2042

Publisher

WILEY
DOI: 10.1111/dom.15057

Keywords

canagliflozin; cardiovascular disease; diabetic nephropathy; type 2 diabetes

Categories

Endocrinology & Metabolism

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.